Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma

Circulating tumor DNA (ctDNA) has been validated across multiple indications in the adjuvant and surveillance settings. We evaluated whether targeted digital sequencing (TARDIS) may distinguish a partial response (PR) from a complete response (CR) among patients with metastatic renal cell carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Chehrazi-Raffle, Alexander, Muddasani, Ramya, Dizman, Nazli, Hsu, JoAnn, Meza, Luis, Zengin, Zeynep B., Malhotra, Jasnoor, Chawla, Neal, Dorff, Tanya, Contente-Cuomo, Tania, Dinwiddie, Devin, McDonald, Bradon R., McDaniel, Timothy, Trent, Jeffrey M., Baehner, Frederick L., Murtaza, Muhammed, Pal, Sumanta K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309555/
https://www.ncbi.nlm.nih.gov/pubmed/37027813
http://dx.doi.org/10.1200/PO.22.00543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309555/
https://www.ncbi.nlm.nih.gov/pubmed/37027813
http://dx.doi.org/10.1200/PO.22.00543

Ejemplares similares